JSPR
NASDAQJasper Therapeutics Inc.
Price$0.88+0.20 (+29.18%)
01:30 PM07:45 PM
News · 26 weeks28-20%
2026-01-182026-07-12
Mix1790d
- SEC Filings10(59%)
- Other5(29%)
- Analyst1(6%)
- M&A1(6%)
Latest news
25 items- SECJasper Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)
- SECJasper Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)
- PRJasper Therapeutics Announces Merger with Kira PharmaceuticalsCombined company positioned to advance portfolio of biologic agents designed to improve outcomes in patients with numerous immunologically-driven disorders Concurrent $132 million private investment with participation from leading life sciences investors and Mirador Therapeutics Kira out-licenses KP-301, a long-acting anti-C5a monoclonal antibody, and KP-402, a small molecule C5a receptor antagonist, to Mirador Therapeutics, for $12 million upon signing and potential development and sales milestone payments Combined financing and transactions expected to fund combined company operations through the second half of 2028, including multiple clinical milestones REDWOOD CITY, Calif. and CAM
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Jasper Therapeutics Inc.SCHEDULE 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)
- SECSEC Form DEFA14A filed by Jasper Therapeutics Inc.DEFA14A - Jasper Therapeutics, Inc. (0001788028) (Filer)
- SECSEC Form DEF 14A filed by Jasper Therapeutics Inc.DEF 14A - Jasper Therapeutics, Inc. (0001788028) (Filer)
- SECJasper Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)
- SECJasper Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)
- PRJasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder ValueREDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that, following an evaluation of current market conditions, its Board of Directors has decided to initiate a comprehensive review of strategic alternatives aimed at maximizing shareholder value. Strategic alternatives being evaluated include, among other options, a sale of assets, licensing of assets, collaborations,
- SECJasper Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)
- ANALYSTJasper Therapeutics downgraded by TD CowenTD Cowen downgraded Jasper Therapeutics from Buy to Hold
- SECSEC Form 10-Q filed by Jasper Therapeutics Inc.10-Q - Jasper Therapeutics, Inc. (0001788028) (Filer)
- SECJasper Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)
- PRJasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateREDWOOD CITY, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended March 31, 2026 and provided a corporate update. "In recent months, we have continued to advance the briquilimab development program in CSU," said Jeet Mahal, President and Chief Executive Officer of Jasper. "Following our positive clinical data update in January, we have conducted a
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Jasper Therapeutics Inc.SCHEDULE 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Jasper Therapeutics Inc.SCHEDULE 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)
- SECAmendment: SEC Form 10-K/A filed by Jasper Therapeutics Inc.10-K/A - Jasper Therapeutics, Inc. (0001788028) (Filer)
- SECJasper Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)
- SECSEC Form 10-K filed by Jasper Therapeutics Inc.10-K - Jasper Therapeutics, Inc. (0001788028) (Filer)
- PRJasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate UpdateREDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter and year ended December 31, 2025 and provided a corporate update. "Briquilimab has demonstrated the potential for a compelling and differentiated profile in both CSU and CIndU, along with proof of concept in asthma," said Jeet Mahal, President and Chief Executive Officer of Jasper. "We
- ANALYSTUBS resumed coverage on Jasper Therapeutics with a new price targetUBS resumed coverage of Jasper Therapeutics with a rating of Neutral and set a new price target of $1.50
- SECSEC Form SCHEDULE 13G filed by Jasper Therapeutics Inc.SCHEDULE 13G - Jasper Therapeutics, Inc. (0001788028) (Subject)
- PRJasper Therapeutics to Present at 46th Annual TD Cowen Healthcare ConferenceREDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that management will participate at the 46th Annual TD Cowen Healthcare Conference, taking place March 2-4, 2026 in Boston, MA. 46th Annual TD Cowen Healthcare ConferenceConference Dates: March 2-4, 2026Presentation Date/Time: Monday, March 2, 2026; 3:50 PM ESTPresentation Format: Fireside Chat A live webcast of the f
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Jasper Therapeutics Inc.SCHEDULE 13D/A - Jasper Therapeutics, Inc. (0001788028) (Subject)
- SECSEC Form SCHEDULE 13G filed by Jasper Therapeutics Inc.SCHEDULE 13G - Jasper Therapeutics, Inc. (0001788028) (Subject)
JSPR FAQ
7 questionsWhat does Jasper Therapeutics Inc. do?
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company develops JSP191, a humanized monoclonal antibody for clearing hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It also develops Jasper eHSC Platform to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.Where does JSPR stock trade?
Jasper Therapeutics Inc. (JSPR) is listed on NASDAQ.What sector and industry is JSPR in?
Jasper Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Jasper Therapeutics Inc. go public?
Jasper Therapeutics Inc. (JSPR) completed its IPO in 2020.What are analysts saying about JSPR?
Jasper Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from TD Cowen: Hold on 2026-05-15.What companies are similar to JSPR?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare JSPR side-by-side with any of them on Quantisnow.How can I track JSPR on Quantisnow?
Quantisnow aggregates Jasper Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow JSPR to receive live email and push alerts on every new disclosure.